6 completed. 3 Phase 4, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Ad5-nCoV vaccine: new trials by email Literature Review of Ad5-nCoV vaccine trials Research Report on Ad5-nCoV vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase IIB Study of Recombinant Novel Coronavirus Vaccine Ad5-nCov - COVID-19 Vaccine | Phase 2 | Completed | Fundación Huésped | 88 | 2021-10-01 | 2025-06-25 |
| Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults Recombinant SARS-CoV-2 Ad5 vectored vaccine, Inactive SARS-CoV-2 vaccine (Vero cell) - COVID-19 | Phase 4 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 300 | 2021-08-26 | 2022-08-16 |
| Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) Recombinant SARS-CoV-2 Ad5 vectored vaccine, Inactive SARS-CoV-2 vaccine (Vero cell) - COVID-19 | Phase 4 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 300 | 2021-05-25 | 2022-03-31 |
| Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against COVID-19, trivalent split influenza vaccine - COVID-19 | Phase 4 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 120 | 2021-04-07 | 2022-04-06 |
| A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Ad5-nCoV - COVID-19 | Phase 1 | Completed | Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | 149 | 2020-09-29 | 2023-05-24 |
| A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector), Placebo - COVID-19 | Phase 2 | Completed | Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | 508 | 2020-04-12 | 2023-05-24 |
COVID-19 (5)
Jiangsu Province Centers for Disease Control and Prevention (3) · Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China (2) · Fundación Huésped (1)
China (5) · Argentina (1)
Jing-Xin Li, PhD (3) · Fengcai Zhu, MD (1)
PMID 32702299, PMID 34324836, PMID 35087233, PMID 35617368, PMID 37360864, PMID 37428653, PMID 42464341